GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide drug shortage has been resolved. The timing of this order was unexpected due to the ongoing litigation between FDA and the Outsourcing Facilities Association (OFA) involving tirzepatide,
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
healthday on MSN20h
Nonarteritic Anterior Ischemic Optic Neuropathy Increased With SemaglutideFor individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...
1don MSN
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
WXMI Grand Rapids, MI on MSN19h
Skin Envy explains Semaglutide and TirzepatideNone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback